Trials / Available
AvailableNCT06948955
Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors
Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Cogent Biosciences, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The purpose of this expanded access program (EAP) is to provide investigational bezuclastinib so that it can be coadministered with sunitinib to patients with a diagnosis of gastrointestinal stromal tumors (GIST) with no comparable or satisfactory alternative therapy options. The combination of bezuclastinib and sunitinib provides broad inhibition of all primary and secondary KIT mutations that commonly occur in GIST.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bezuclastinib | Drug: Bezuclastinib |
| DRUG | Sunitinib | Drug: Sunitinib (locally sourced) |
Timeline
- First posted
- 2025-04-29
- Last updated
- 2026-04-02
Locations
17 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT06948955. Inclusion in this directory is not an endorsement.